The Carlyle Group is rumoured to be considering a bid for the generics business of German Chemical-pharmaceutical company Merck. The sale of the division is expected to attract further private equity firms, with Bain Capital, Apax Partners, KKR and Warburg Pincus said to be preparing a bid. Additionally, strategic investors like Icelandic Actavis, Israeli Teva Pharmaceutical Industries Indian Ranbaxy Laboratories and Dr Reddy’s Laboratories are said to be potential bidders.
Company will now operate as Aurora Lichtwerke and was sold as part of a non-core asset divestment
Canadian GP previously owned around 20% of the listed education company
French bank BPCE mandated advisers to sell the Germany-based digital banking platform in 2018
ECI is currently investing from its ECI 11 fund, which closed on £700m on July 2018